137 related articles for article (PubMed ID: 28192780)
21. A retrospective cohort study of metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy, with an exploratory analysis of changing serum carcinoembryonic antigen levels.
Ng SL; Burns WI; Snyder RD; Newnham GM; McLachlan SA; Liew D; Dowling AJ
Asia Pac J Clin Oncol; 2012 Jun; 8(2):172-9. PubMed ID: 22524576
[TBL] [Abstract][Full Text] [Related]
22. Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial.
Yoshino T; Obermannová R; Bodoky G; Garcia-Carbonero R; Ciuleanu T; Portnoy DC; Kim TW; Hsu Y; Ferry D; Nasroulah F; Tabernero J
Eur J Cancer; 2017 Jun; 78():61-69. PubMed ID: 28412590
[TBL] [Abstract][Full Text] [Related]
23. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
Cremolini C; Loupakis F; Antoniotti C; Lupi C; Sensi E; Lonardi S; Mezi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Carlomagno C; Allegrini G; Chiara S; D'Amico M; Granetto C; Cazzaniga M; Boni L; Fontanini G; Falcone A
Lancet Oncol; 2015 Oct; 16(13):1306-15. PubMed ID: 26338525
[TBL] [Abstract][Full Text] [Related]
24. Bevacizumab in metastatic colorectal cancer and carcino-embryonic antigen kinetics: case report and review of literature.
de Andrade DP; Lima JP; Lima AD; Sasse AD; dos Santos LV
Anticancer Drugs; 2011 Jun; 22 Suppl 2():S15-7. PubMed ID: 21768792
[TBL] [Abstract][Full Text] [Related]
25. Inflammation-based prognostic system predicts postoperative survival of colorectal cancer patients with a normal preoperative serum level of carcinoembryonic antigen.
Ishizuka M; Nagata H; Takagi K; Iwasaki Y; Kubota K
Ann Surg Oncol; 2012 Oct; 19(11):3422-31. PubMed ID: 22576063
[TBL] [Abstract][Full Text] [Related]
26. The dynamic monitoring of CEA in response to chemotherapy and prognosis of mCRC patients.
Yu P; Zhou M; Qu J; Fu L; Li X; Cai R; Jin B; Teng Y; Liu J; Shi J; Zhang J
BMC Cancer; 2018 Nov; 18(1):1076. PubMed ID: 30404612
[TBL] [Abstract][Full Text] [Related]
27. Total cell-free DNA, carcinoembryonic antigen, and C-reactive protein for assessment of prognosis in patients with metastatic colorectal cancer.
Spindler KG; Demuth C; Sorensen BS; Johansen JS; Nielsen D; Pallisgaard N; Hoegdall E; Pfeiffer P; Vittrup Jensen B
Tumour Biol; 2018 Nov; 40(11):1010428318811207. PubMed ID: 30486767
[TBL] [Abstract][Full Text] [Related]
28. Circulating endothelial cells predict for response to bevacizumab-based chemotherapy in metastatic colorectal cancer.
Matsusaka S; Suenaga M; Mishima Y; Takagi K; Terui Y; Mizunuma N; Hatake K
Cancer Chemother Pharmacol; 2011 Sep; 68(3):763-8. PubMed ID: 21170650
[TBL] [Abstract][Full Text] [Related]
29. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer.
Iinuma H; Watanabe T; Mimori K; Adachi M; Hayashi N; Tamura J; Matsuda K; Fukushima R; Okinaga K; Sasako M; Mori M
J Clin Oncol; 2011 Apr; 29(12):1547-55. PubMed ID: 21422427
[TBL] [Abstract][Full Text] [Related]
30. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Simkens LH; van Tinteren H; May A; ten Tije AJ; Creemers GJ; Loosveld OJ; de Jongh FE; Erdkamp FL; Erjavec Z; van der Torren AM; Tol J; Braun HJ; Nieboer P; van der Hoeven JJ; Haasjes JG; Jansen RL; Wals J; Cats A; Derleyn VA; Honkoop AH; Mol L; Punt CJ; Koopman M
Lancet; 2015 May; 385(9980):1843-52. PubMed ID: 25862517
[TBL] [Abstract][Full Text] [Related]
31. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
Schmoll HJ; Cunningham D; Sobrero A; Karapetis CS; Rougier P; Koski SL; Kocakova I; Bondarenko I; Bodoky G; Mainwaring P; Salazar R; Barker P; Mookerjee B; Robertson J; Van Cutsem E
J Clin Oncol; 2012 Oct; 30(29):3588-95. PubMed ID: 22965961
[TBL] [Abstract][Full Text] [Related]
32. Prognostic factors for disease-free survival after preoperative chemotherapy followed by curative resection in patients with colorectal cancer harboring hepatic metastasis: a single-institute, retrospective analysis in Asia.
Yi JH; Kim H; Jung M; Shin SJ; Choi JS; Choi GH; Baik SH; Min BS; Kim NK; Ahn JB
Oncology; 2013; 85(5):283-9. PubMed ID: 24217184
[TBL] [Abstract][Full Text] [Related]
33. CEA Response and Depth of Response (DpR) to Predict Clinical Outcomes of First-Line Cetuximab Treatment for Metastatic Colorectal Cancer.
Sunakawa Y; Tsuji A; Denda T; Segawa Y; Negoro Y; Shimada K; Kochi M; Nakamura M; Kotaka M; Tanioka H; Takagane A; Tani S; Yamaguchi T; Watanabe T; Takeuchi M; Fujii M; Ichikawa W
Target Oncol; 2017 Dec; 12(6):787-794. PubMed ID: 29064002
[TBL] [Abstract][Full Text] [Related]
34. Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer.
Bruhn MA; Townsend AR; Khoon Lee C; Shivasami A; Price TJ; Wrin J; Arentz G; Tebbutt NC; Hocking C; Cunningham D; Hardingham JE;
Int J Cancer; 2014 Aug; 135(3):731-41. PubMed ID: 24374727
[TBL] [Abstract][Full Text] [Related]
35. Impact of Pre-Treatment Lactate Dehydrogenase Levels on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer.
Passardi A; Scarpi E; Tamberi S; Cavanna L; Tassinari D; Fontana A; Pini S; Bernardini I; Accettura C; Ulivi P; Frassineti GL; Amadori D
PLoS One; 2015; 10(8):e0134732. PubMed ID: 26244985
[TBL] [Abstract][Full Text] [Related]
36. Prognostic factors and survival after resection of colorectal liver metastasis in the era of preoperative chemotherapy: an 11-year single-centre study.
John SK; Robinson SM; Rehman S; Harrison B; Vallance A; French JJ; Jaques BC; Charnley RM; Manas DM; White SA
Dig Surg; 2013; 30(4-6):293-301. PubMed ID: 23969407
[TBL] [Abstract][Full Text] [Related]
37. Combined detection of preoperative serum CEA, CA19-9 and CA242 improve prognostic prediction of surgically treated colorectal cancer patients.
Wang J; Wang X; Yu F; Chen J; Zhao S; Zhang D; Yu Y; Liu X; Tang H; Peng Z
Int J Clin Exp Pathol; 2015; 8(11):14853-63. PubMed ID: 26823815
[TBL] [Abstract][Full Text] [Related]
38. c-MET Overexpression in Colorectal Cancer: A Poor Prognostic Factor for Survival.
Lee SJ; Lee J; Park SH; Park JO; Lim HY; Kang WK; Park YS; Kim ST
Clin Colorectal Cancer; 2018 Sep; 17(3):165-169. PubMed ID: 29576428
[TBL] [Abstract][Full Text] [Related]
39. Usefulness of the serum carcinoembryonic antigen kinetic for chemotherapy monitoring in patients with unresectable metastasis of colorectal cancer.
Iwanicki-Caron I; Di Fiore F; Roque I; Astruc E; Stetiu M; Duclos A; Tougeron D; Saillard S; Thureau S; Benichou J; Paillot B; Basuyau JP; Michel P
J Clin Oncol; 2008 Aug; 26(22):3681-6. PubMed ID: 18669452
[TBL] [Abstract][Full Text] [Related]
40. Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study.
Sogabe S; Komatsu Y; Yuki S; Kusumi T; Hatanaka K; Nakamura M; Kato T; Miyagishima T; Hosokawa A; Iwanaga I; Sakata Y; Asaka M
Jpn J Clin Oncol; 2011 Apr; 41(4):490-7. PubMed ID: 21303790
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]